Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial.

ABSTRACT:

Objective

To compare the effectiveness and safety of nab-paclitaxel, cisplatin, and capecitabine (nab-TPC) with gemcitabine and cisplatin as an alternative first line treatment option for recurrent or metastatic nasopharyngeal carcinoma.

Design

Phase 3, open label, multicentre, randomised trial.

Setting

Four hospitals located in China between September 2019 and August 2022.

Participants

Adults (≥18 years) with recurrent or metastatic nasopharyngeal carcinoma.

Interventions

Patients were randomised in a 1:1 ratio to treatment with either nab-paclitaxel (200 g/m² on day 1), cisplatin (60 mg/m² on day 1), and capecitabine (1000 mg/m² twice on days 1-14) or gemcitabine (1 g/m² on days 1 and 8) and cisplatin (80 mg/

SUBMITTER: Liu GY 

PROVIDER: S-EPMC11190944 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature